What is Prokarium?
Prokarium operates as a specialized biopharmaceutical entity focused on the intersection of synthetic biology and immunology. The company's core innovation, the Living Cures platform, utilizes engineered bacteria to deliver programmable therapeutic payloads directly to tumor sites. This approach is designed to enhance the efficacy of existing immunotherapies while minimizing systemic toxicity. With a primary focus on bladder cancer, Prokarium is currently scaling its research and development operations to transition its lead candidates through clinical trials, aiming to redefine the standard of care for patients with limited therapeutic options.
How much funding has Prokarium raised?
Prokarium has raised a total of $66.7M across 4 funding rounds:
Series A
$10M
Other Financing Round
$5.7M
Series B
$21M
Other Financing Round
$30M
Series A (2018): $10M, investors not publicly disclosed
Other Financing Round (2019): $5.7M led by Wellcome Trust
Series B (2020): $21M supported by Future Fund, Riyadh Valley Company, Korea Investment Partners, and Flerie Invest
Other Financing Round (2023): $30M, investors not publicly disclosed
Key Investors in Prokarium
Wellcome Trust
Wellcome is an independent global charitable foundation based in London that supports discovery research and tackles urgent health challenges, funding science, policy and public engagement to improve health for people everywhere through grants, partnerships and advocacy.
Future Fund
Future Fund was established in 2006 to invest for the benefit of future generations of Australians, helping to meet public sector superannuation liabilities and easing pressure on government finances.
Riyadh Valley Company
Riyadh Valley is the investment arm of King Saud University, supporting entrepreneurs and early-stage ventures by providing capital, strategic advice, and access to innovation ecosystems.
What's next for Prokarium?
With the recent influx of capital, Prokarium is poised to advance its clinical-stage assets and expand its Living Cures platform capabilities. The strategic roadmap involves intensifying research into multi-modal cancer treatments and strengthening the company's intellectual property portfolio. As the firm moves into its next phase of growth, the focus will remain on achieving key clinical milestones and establishing partnerships that facilitate the commercialization of its microbial-based therapies. Investors and stakeholders are closely monitoring the company's progress as it seeks to validate its platform in human trials, potentially setting a new benchmark for precision oncology.
See full Prokarium company page
